Hikma (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. In all, the company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics. Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The most popular products from the Branded division are: Amoclan, Omnisef, Blopress, Suprax and other. Hik share price is set and traded on the London Stock Exchange (LSE). The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, It became the first Arab company to export pharmaceutical products to the US. The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquiring helped Hikma to establish itself as the world’s leading provider in its industry.
Hikma made an initial public offering on 11 November 2005, and Hik share price was listed on the London Stock Exchange for the first time, raising gross proceeds of $124 million.
In May 2014, Hikma Pharmaceuticals agreed to purchase assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, drastically increasing its presence in the injected medicine market.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma position in a non-injectables business in the US market.
Hikma have been recognized as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a raw: from 2014 to 2017.
Follow Capital.com to stay tuned to the Hik share price.
